ALDX Stock Overview A biotechnology company, develops and commercializes medicines for immune-mediated diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Aldeyra Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Aldeyra Therapeutics Historical stock prices Current Share Price US$4.88 52 Week High US$6.55 52 Week Low US$2.71 Beta 1.37 1 Month Change 0.62% 3 Month Change -12.54% 1 Year Change 40.23% 3 Year Change 17.03% 5 Year Change -24.92% Change since IPO -32.22%
Recent News & Updates
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold US$76k worth of stock Aug 15
Chief Development Officer notifies of intention to sell stock Aug 14
Price target increased by 8.1% to US$10.00 Aug 12
New minor risk - Share price stability Aug 08 See more updates
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold US$76k worth of stock Aug 15
Chief Development Officer notifies of intention to sell stock Aug 14
Price target increased by 8.1% to US$10.00 Aug 12
New minor risk - Share price stability Aug 08
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap Aug 08
Consensus EPS estimates fall by 209% Aug 08
New minor risk - Profitability Aug 05
No longer forecast to breakeven Aug 05 Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Aug 02
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt? Jun 21
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable Jun 20
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease Jun 15
Consensus EPS estimates upgraded to US$0.18 loss May 23
Forecast to breakeven in 2026 May 22
Consensus EPS estimates fall by 163% May 12
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 09
No longer forecast to breakeven May 06
New minor risk - Profitability May 05
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024 Apr 23
New minor risk - Profitability Apr 03
No longer forecast to breakeven Apr 03
Forecast to breakeven in 2024 Mar 29
New minor risk - Profitability Mar 28
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease Mar 28
CEO, President & Director recently sold US$581k worth of stock Mar 14
CEO, President & Director notifies of intention to sell stock Mar 13
Forecast to breakeven in 2024 Mar 11
New minor risk - Profitability Mar 10
Forecast to breakeven in 2024 Mar 08
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load? Feb 16
Consensus revenue estimates increase by 55% Jan 30
Consensus revenue estimates increase by 57% Jan 05
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis Dec 19
Consensus revenue estimates increase by 600% Dec 06
New minor risk - Profitability Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 28
Consensus revenue estimates decrease by 82%, EPS upgraded Nov 10
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt? Nov 06
New minor risk - Market cap size Oct 19
New minor risk - Profitability Oct 18
Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease Oct 17
Consensus revenue estimates decrease by 61%, EPS upgraded Oct 17
Price target decreased by 13% to US$17.86 Oct 16
CEO, President & Director exercised options and sold US$492k worth of stock Sep 13
Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc Sep 01
Consensus revenue estimates increase by 36% Aug 22
Consensus revenue estimates decrease by 73%, EPS upgraded Aug 10
Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc Aug 02
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough Jun 28
Consensus revenue estimates increase by 15% Jun 22
Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis Jun 16
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023 May 25
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? Mar 26
Consensus revenue estimates decrease by 41%, EPS upgraded Mar 16
Price target increased by 8.4% to US$21.83 Mar 12
Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials Feb 18
Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease Feb 08
Forecast to breakeven in 2025 Feb 02
Insufficient new directors Feb 01
Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma Dec 22
Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial Dec 14
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Dec 03
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease Nov 30
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt? Nov 19
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy Oct 07
Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA Sep 15
Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment Sep 14
Insider recently bought US$1.1m worth of stock Aug 04
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization Aug 04
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way? Aug 03
Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial Jul 13
Aldeyra says trial for dry eye disease candidate reached key goals Jul 12
CEO, President & Director recently bought US$60k worth of stock Jun 28
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Tranquility-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease Jun 09
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 26
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 25
Aldeyra Therapeutics Announces That Post-Hoc Analysis Using Computer Automated Grading of Phase 3 Tranquility Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap over Vehicle for Primary Endpoint of Ocular Redness May 19
Price target decreased to US$20.89 Apr 27
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? Apr 19
Aldeyra Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 Tranquility-2 Trial in Patients with Dry Eye Disease Apr 06
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day Mar 30
No longer forecast to breakeven Mar 19 Aldeyra Therapeutics, Inc. Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa Mar 10
Forecast to breakeven in 2024 Feb 24
Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts Feb 17
Aldeyra Therapeutics, Inc. Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model Feb 02
Forecast to breakeven in 2024 Jan 25
Aldeyra Therapeutics, Inc Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra Jan 12
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Jan 05
Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap Dec 23 Shareholder Returns ALDX US Biotechs US Market 7D -0.4% -3.6% -2.4% 1Y 40.2% -2.7% 23.3%
See full shareholder returns
Return vs Market: ALDX exceeded the US Market which returned 23.3% over the past year.
Price Volatility Is ALDX's price volatile compared to industry and market? ALDX volatility ALDX Average Weekly Movement 8.7% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ALDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALDX's weekly volatility (9%) has been stable over the past year.
About the Company Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Show more Aldeyra Therapeutics, Inc. Fundamentals Summary How do Aldeyra Therapeutics's earnings and revenue compare to its market cap? ALDX fundamental statistics Market cap US$290.60m Earnings (TTM ) -US$44.80m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALDX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$44.80m Earnings -US$44.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.75 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 18.0%
How did ALDX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:06 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Aldeyra Therapeutics, Inc. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju Aegis Capital Corporation Keay Nakae Ascendiant Capital Markets LLC Esther Lannie Hong Berenberg
Show 19 more analysts 
